16 stories found
Teva Pharmaceuticals has announced that its experimental anti-IL-15 antibody therapy successfully met its primary endpoints in a mid-stage clinical trial for celiac disease. The positive results further validate the drug's potential as a pipeline-in-a-product candidate.
Several companies, including Hyperscale Data, Pepsico, Royalty Pharma, Anfield Universal Fixed Income ETF, Exchange Income, and Qualcomm, have declared their latest dividends to shareholders.
Several companies, including ATN International, EVERTEC, Montrose Environmental, Phibro Animal, UGI, and TKO, have released their latest quarterly financial results. While some companies reported earnings that beat analyst expectations, others missed revenue or EPS forecasts.
Royalty Pharma has announced a dividend of $0.235 per share.
Royalty Pharma has entered into a $500 million research and development funding collaboration with Johnson & Johnson, specifically partnering to develop new treatments for autoimmune diseases.
TD Cowen has raised its price target for Royalty Pharma Plc (RPRX) from $45 to $50, providing reasons for the increase.
The article compares Royalty Pharma plc (RPRX) and AstraZeneca PLC (AZN) to determine which biopharma company offers a more promising growth story based on their respective business models.
Royalty Pharma, plc (RPRX) saw its stock rally after reporting earnings that surpassed expectations for the first quarter.
Multiple companies have released their recent financial performance, detailing GAAP or Non-GAAP earnings per share and revenue figures. These reports indicate whether the companies met, beat, or missed analyst expectations for their latest reporting period.
Royalty Pharma plc (RPRX) demonstrated resilience in the first quarter, achieving a significant gain of 25.6% in its performance.
Royalty Pharma plc (RPRX) has been given a $51 target as its growth outlook for 2026 surpasses market expectations, indicating strong future performance.
Several companies, including NuScale Power, Cadre Holdings, and NiSource, have released their Q2 2026 earnings previews. Superior Group of Companies, Inc. also provided a summary of its Q2 2026 earnings call.
Royalty Pharma (RPRX) is capitalizing on the biotech funding gap, achieving increasing returns and strengthening its market dominance.
An analysis suggests that Royalty Pharma Plc (RPRX) is currently one of the most undervalued biotech stocks available for purchase, highlighting its investment potential.
Royalty Pharma and Johnson & Johnson have finalized a $500 million deal concerning an autoimmune drug, marking a significant collaboration in the pharmaceutical sector.
Susquehanna analysts identify an opportunity for Fidelity National Information Services, Inc. (FIS) due to an improving end-market environment.